New standards of care for treatment of diffuse large B-cell lymphoma

被引：1

作者：

Abeyakoon, Chathuri ^{[1
,2
,3
]}

Gregory, Gareth P. ^{[1
,2
]}

机构：

[1] Monash Univ, Sch Clin Sci Monash Hlth, Lymphoma Res Grp, Clayton, Vic, Australia

[2] Monash Hlth, Monash Haematol, 246 Clayton Rd, Clayton, Vic 3168, Australia

[3] Princess Margaret Hosp, Dept Med Oncol & Haematol, Toronto, ON, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 04期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

chemotherapy; DLBCL; immunotherapy; lymphomas; CHOP CHEMOTHERAPY; RITUXIMAB; CYCLES;

D O I：

10.1111/bjh.19295

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of newly diagnosed diffuse large B-cell lymphoma with rituximab and CHOP (R-CHOP) has been largely unchanged for the last two decades. The Guideline by Fox et al. provides new evidence-based therapeutic strategies informed by positive results of randomised clinical trials.Commentary on: Fox et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19273.

引用

页码：1132 / 1134

页数：3

共 9 条

[1] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier, B
Lepage, E
Brière, J
Herbrecht, R
Tilly, H
Bouabdallah, R
Morel, P
Van den Neste, E
Salles, G
Gaulard, P
Reyes, F
Gisselbrecht, C
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
[2] The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline
Fox, Christopher P.
Chaganti, Sridhar
Mcilroy, Graham
Barrington, Sally F.
Burton, Cathy
Cwynarski, Kate
Eyre, Toby A.
Illidge, Timothy
Kalakonda, Nagesh
Kuhnl, Andrea
Mckay, Pam
Davies, Andrew J.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1178 - 1192
[3] Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
Persky, Daniel O.
Unger, Joseph M.
Spier, Catherine M.
Stea, Baldassarre
LeBlanc, Michael
McCarty, Matthew J.
Rimsza, Lisa M.
Fisher, Richard I.
Miller, Thomas P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2258 - 2263
[4] Poeschel V, 2019, LANCET, V394, P2271, DOI 10.1016/S0140-6736(19)33008-9
[5] Roschewski M, 2023, HAEMATOL ONCOL, V41, P177, DOI 10.1002/ hon.3163_112
[6] Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
Russler-Germain, David A.
Cliff, Edward R. Scheffer
Bartlett, Nancy L.
[J]. BLOOD, 2023, 142 (25) : 2216 - 2219
[7] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, M.
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua-Burgues, Juan M.
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher R.
Salles, Gilles
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) : 351 - 363
[8] Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wilson, Wyndham H.
Wright, George W.
Huang, Da Wei
Hodkinson, Brendan
Balasubramanian, Sriram
Fan, Yue
Vermeulen, Jessica
Shreeve, Martin
Staudt, Louis M.
[J]. CANCER CELL, 2021, 39 (12) : 1643 - +
[9] A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
Wright, George W.
Huang, Wei
Phelan, James D.
Coulibaly, Zana A.
Roulland, Sandrine
Young, Ryan M.
Wang, James Q.
Schmitz, Roland
Morin, Ryan D.
Tang, Jeffrey
Jiang, Aixiang
Bagaev, Aleksander
Plotnikova, Olga
Kotlov, Nikita
Johnson, Calvin A.
Wilson, Wyndham H.
Scott, David W.
Staudt, Louis M.
[J]. CANCER CELL, 2020, 37 (04) : 551 - +

← 1 →